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Associação entre indoxil sulfato e histomorfometria óssea em 
pacientes renais crônicos pré-diálise
Association between indoxyl sulfate and bone 
histomorphometry in pre-dialysis chronic kidney disease 
patients
Introdução: Estudos experimentais 
indicam que o indoxil sulfato (IS), uma 
toxina urêmica ligada à proteína, pode 
estar envolvido no desenvolvimento da 
osteodistrofia renal. Objetivo: Avaliar 
a associação entre os níveis séricos de 
IS e parâmetros bioquímicos do meta-
bolismo mineral e da histomorfometria 
óssea em uma coorte de pacientes com 
doença renal crônica (DRC) pré-diáli-
se. Métodos: Análise post-hoc de um 
estudo que avaliou a associação entre 
calcificação coronariana e histomor-
fometria óssea em 49 pacientes (idade: 
52 ± 10 anos; 67% sexo masculino; 
taxa de filtração glomerular estimada: 
36 ± 17 ml/min). Os níveis séricos de 
IS foram dosados. Resultados: Pacien-
tes com DRC estágio 2 e 3 apresen-
taram uma taxa de formação óssea 
baixa. Pacientes com DRC estágio 4 e 
5 apresentaram volume osteoide, su-
perfícies osteoblástica e osteoclástica, 
volume de fibrose e taxa de formação 
óssea significativamente maiores e in-
tervalo de mineralização significati-
vamente menor que os pacientes com 
DRC estágio 2 e 3. Os níveis séricos de 
IS associaram-se positivamente com a 
taxa de formação óssea, volume osteoi-
de, superfície osteoblástica e volume de 
fibrose. A análise de regressão multiva-
riada identificou que o IS é um fator 
independente determinante da superfí-
cie osteoblástica e fibrose. Uma tendên-
cia similar foi observada para a taxa 
de formação óssea. Conclusão: Nosso 
estudo sugere que, na DRC pré-dialíti-
ca, o IS correlaciona-se positivamente 
com a formação óssea.
Resumo
Palavras-chave: indoxil sulfato; insuficiência 
renal crônica; osteodistrofia renal; uremia.
Introduction: Experimental studies have 
suggested that indoxyl sulfate (IS), a 
protein-bound uremic toxin, may be 
involved in the development of renal 
osteodystrophy. Objective: evaluate 
the association between IS levels and 
biochemical parameters related to 
mineral metabolism and bone histo-
morphometry in a cohort of pre-dialysis 
chronic kidney disease (CKD) patients. 
Methods: This is a post-hoc analysis of 
an observational study evaluating the 
association between coronary calcifica-
tion and bone biopsy findings in 49 pa-
tients (age: 52 ± 10 years; 67% male; 
estimated glomerular filtration rate: 
36 ± 17 ml/min). Serum levels of IS were 
measured. Results: Patients at CKD 
stages 2 and 3 presented remarkably 
low bone formation rate. Patients at 
CKD stages 4 and 5 presented signifi-
cantly higher osteoid volume, osteoblast 
and osteoclast surface, bone fibrosis 
volume and bone formation rate and a 
lower mineralization lag time than CKD 
stage 2 and 3 patients. We observed a 
positive association between IS levels on 
one hand and the bone formation rate, 
osteoid volume, osteoblast surface and 
bone fibrosis volume on the other. Mul-
tivariate regression models confirmed 
that the associations between IS levels 
and osteoblast surface and bone fibrosis 
volume were both independent of demo-
graphic and biochemical characteristics 
of the study population. A similar trend 
was observed for the bone formation 
rate. Conclusions: Our findings demon-
strated that IS is positively associated 
with bone formation rate in pre-dialysis 
CKD patients.
AbstRAct
Keywords: renal insufficiency, chronic; in-
doxyl sulfate; renal osteodystrophy; ure-
mia.
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IntRoductIon
Disturbances of bone and mineral metabolism are 
common in chronic kidney disease (CKD) patients 
and are associated with increased morbidity and 
reduced quality of life.1,2 The various pathological 
bone alterations found in CKD patients are collecti-
vely referred to as renal osteodystrophy (ROD) and 
include alterations in bone histology, which can be 
quantified by the histomorphometric assessment of 
bone biopsies.
It is known that ROD begins very early in 
the course of CKD.3,4 Many factors have been 
incriminated in the pathophysiology of this condition, 
including calcium, phosphate, parathyroid hormone 
(PTH), vitamin D and its analogues, fibroblast growth 
factor-23 (FGF-23) and, more recently, sclerostin.5 
Several other important, quantifiable solutes that 
have negative biological effects and are retained in 
the body as the uremic condition progresses - the 
so-called uremic toxins - have been implicated as well.
Indoxyl sulfate (IS) is a protein-bound uremic 
toxin derived from the metabolism of dietary trypto-
phan. Briefly, tryptophan is metabolized into indole by 
intestinal bacteria and, after intestinal absorption, is 
further converted to IS in the liver. It is excreted by the 
kidneys via proximal tubular secretion. Consequently, 
IS accumulates in the blood of patients with impaired 
renal function. Moreover, IS’s high binding affinity 
for albumin means that it cannot be efficiently re-
moved by conventional hemodialysis.6 The role of IS 
as a uremic toxin was first revealed by its accelerating 
effects on CKD progression,7 possibly via a reduction 
in proximal tubular cell viability due to increased 
oxidative stress.8 Iwazaki et al.9 subsequently used a 
rat model of kidney failure associated with low bone 
turnover to show that IS accumulation was related to 
lower bone formation rate and the down-regulation 
of osteoblast-related genes. This condition was im-
proved by treatment with the oral adsorbent AST-120 
(probably by reducing IS levels). The same group sub-
sequently showed that IS reduced PTH-induced cAMP 
production, PTH receptor (PTH1R) gene expression 
and cell viability in primary osteoblast cultures.10 
More recently, Mozar et al.11 have demonstrated that 
IS inhibits osteoclast differentiation and function. In 
the clinical setting, Goto et al.12 have reported a nega-
tive association between IS and serum markers of bone 
turnover, independent of PTH levels, in a cohort of 47 
hemodialysis patients. These observations prompted 
the hypothesis whereby accumulation of IS is in-
volved in the development of renal osteodystrophy. 
To date, no study assessed by bone histomorphom-
etry has been performed to evaluate this hypothesis.
The present study sought to evaluate the associa-
tion between circulating indoxyl sulfate (IS), a pro-
tein-bound uremic toxin, and biochemical parame-
ters related to mineral metabolism [such as calcium, 
phosphate, bone-specific alkaline phosphatase, intact-
PTH, FGF-23, 25(OH) vitamin D3 (25D) and 1,25 
(OH)2 vitamin D3 (1,25 D)] and histomorphometric 
parameters in a cohort of prevalent, treatment-naïve 
pre-dialysis CKD patients.
mAteRIAl And methods
SubjectS And Study deSign
This is a post-hoc analysis of a cross-sectional study 
that evaluated the association between coronary 
artery calcification and bone histomorphometric 
parameters in a cohort of prevalent, pre-dialysis CKD 
patients from an outpatient nephrology clinic in São 
Paulo, Brazil.13 Patients were 18 years old or over, 
with 24-hour creatinine clearance rates of between 
15 and 90 ml/min/m2. All had been monitored by 
a nephrologist for at least 3 months and had not 
received any phosphate binders, vitamin D analogues 
or corticosteroids. Included patients underwent 
clinical and physical examinations. There was no 
evidence of inflammatory, neoplastic or infectious 
disease in any subject. Weight and height were used 
to calculate the body mass index (BMI). For any given 
patient, laboratory tests and the bone biopsy were 
performed within 30 days of patient selection.
All patients gave their informed, written consent. 
The study protocol was reviewed and approved 
by the local institutional review board and was 
performed in accordance with the ethical principles 
of the Declaration of Helsinki.
lAborAtory teStS
Fasting blood samples were assayed for creatinine, 
ionized calcium, phosphorus, alkaline phosphatase 
(reference ranges: < 270 U/L for men < and 240 
U/L for women), bone-specific alkaline phosphatase 
(enzyme immunoassay from Metra Biosystems 
Inc, Mountain View, CA, USA; reference range: 
11.6 to 42.7 U/L for men and 15 to 41.3 U/L for 
women), intact PTH (iPTH; Immulite Assay, DPC, 
Los Angeles, CA, USA; reference range: 10 to 65 
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pg/ml), FGF-23 (ELISA from Kainos Laboratories, 
Tokyo, Japan; reference range: 28.9 ± 1.1 pg/
ml), 1,25 D (radioimmunoassay, Gamma counter, 
Perkin Elmer, Brazil, reference range: 15.9 to 55.6 
pg/ml) and 25D (radioimmunoassay, DiaSorin®, 
Stillwater, MN, USA; reference range: 18 to 62 
ng/dL). For determination of serum total IS levels, 
samples were deproteinized by heat denaturation 
and analyzed by reverse-phase, high-performance 
liquid chromatography. Concentrations were then 
determined by fluorescence detection (excitation 
at 280 nm and emission at 340 nm for IS).14 The 
same method was used for free IS determinations, 
except that serum samples were ultrafiltered through 
a Centrifree (Millipore), prior to deproteinization. 
The reference values for total and free IS in our 
healthy control subjects (n = 20) were 0.090 ± 0.034 
mg/dL and 0.016 ± 0.004 mg/dL, respectively.
In order to estimate the true GFR as accurately as 
possible from serum creatinine levels, we applied the 
recently published “CKD-EPI” equation.6 For descrip-
tive purposes, patients were then classified into CKD 
stages according to the National Kidney Foundation’s 
K/DOQI guidelines.15 Once there were low numbers 
of patients in CKD stages 2 and 5, the study popula-
tion was pooled into two groups (CKD stages 2-3 and 
stages 4-5) for descriptive and analytical purposes.
bone biopSy
Bone samples were taken from the iliac crest af-
ter double tetracycline labeling. Bone fragments 
underwent standard histological processing.8 
Semiautomatic bone histomorphometric analy-
sis was performed using Osteomeasure software 
(Osteometrics Inc, Atlanta, GA), as previously des-
cribed.13 The analyzed histomorphometric parame-
ters were those proposed by the American Society 
of Bone and Mineral Research Histomorphometry 
Nomenclature Committee.16 Reference ranges used 
for static parameters were obtained from local con-
trols,17 whereas dynamic parameters followed those 
described elsewhere.18
Selected histomorphometric parameters for bone 
turnover [bone formation rate/bone surface (BFR/BS)], 
mineralization [mineralization lag time (Mlt)] and 
volume [trabecular bone volume (BV/TV)], as well 
as the osteoblast surface/bone surface (Ob.S/BS), 
osteoid volume/bone volume (OV/BV), osteoclast 
surface/bone surface (Oc.S/BS), eroded surface/bone 
surface (ES/BS) and fibrosis volume (Fb.V) were 
described according to the published guidelines on 
ROD classification.1
StAtiSticAl AnAlySiS
Data are expressed as mean ± SD, median and range or 
frequency. For parameters presenting a non-Gaussian 
distribution, values were log-normalized prior to use 
in tests that require normally distributed variables. 
Intergroup comparisons were performed using a χ2 
test for categorical variables and the Student’s t-test 
or the Mann-Whitney test for continuous variables. 
Univariate linear regression models were used to 
check the associations between serum total IS levels 
and markers of mineral metabolism, as well as bone 
histomorphometric parameters. Variables selected 
in univariate analyses were fed into multivariate 
linear regression models to verify the independence 
of identified associations. A p value ≤ 0.05 was 
considered to be statistically significant. All statistical 
analyses were performed using PASW® statistics 
software, version 18.0.
The authors had full access to the data and take 
full responsibility for their integrity. All authors have 
read and agreed to the manuscript as written.
Results
The patients were preponderantly male (67%) and 
white race (49%), with 40% presenting diabetes 
mellitus as a comorbid condition. The mean ± SD age 
was 52 ± 10 years and the median time since CKD 
diagnosis was 30 months (range: 15 to 83 months). 
Hypertensive nephrosclerosis was the most frequent 
etiology for CKD (39%), followed by diabetic ne-
phropathy (31%). The mean estimated GFR in the 
study cohort was 36 ± 17 ml/min (10% at CKD 
stage 2.49% at CKD stage 3, 35% at CKD stage 4 
and 6% at CKD stage 5, according to the National 
Kidney Foundation’s K/DOQI guidelines).19 Mean 
albumin and hemoglobin values (4.3 ± 0.4 g/dL and 
13 ± 2 g/dL, respectively) were within the normal 
reference ranges. It is noteworthy that most of the 
patients (60%) had sufficient 25D levels (i.e. 25D ≥ 
30 ng/ml) and only 10% of the study patients presen-
ted vitamin D deficiency (defined as 25D ≤ 15 ng/ml).20
Table 1 shows information on biochemical and 
hormonal characteristics, by CKD stage. Serum 
levels of phosphate, iPTH, FGF-23, bone-specific 
alkaline phosphatase, as well as total and free IS 
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were significantly elevated in patients at CKD stages 
4 and 5, in comparison with CKD stage 2 and 3 
patients. Additionally, serum levels of bicarbonate, 
25D and 1,25 D were lower in CKD stage 4 and 
5 patients than in CKD stage 2 and 3 patients. As 
expected (Figure 1), there was a significant, negative 
association between serum total IS and the eGFR. 
Interestingly, total and free IS serum levels were 
already elevated in patients at CKD stages 2 and 3, 
when compared with 20 healthy controls (mean ± SD 
total IS of 0.165 ± 0.079 vs. 0.090 ± 0.034 mg/dL, 
p = 0.001, and mean ± SD free IS of 0.030 ± 0.006 
vs. 0.016 ± 0.004 mg/dL, p < 0.001, respectively). It 
is noteworthy that there were no differences between 
CKD stage subgroups in terms of age, gender, race, 
BMI, diabetes status or time from CKD diagnosis 
(data not shown).
Table 2 shows selected bone histomorphometric 
parameters by CKD stage. Patients at CKD stages 
2 and 3 presented remarkably low bone formation 
rate. In comparison with the latter subjects, patients 
at CKD stages 4 and 5 presented significantly higher 
osteoid volume, osteoblast surface, osteoclast surface, 
fibrosis volume and bone formation rate, and showed 
a trend toward lower mineralization lag time. There 
was no intergroup difference in trabecular bone 
volume. Importantly, none of the cohort members 
stained positively for aluminum at bone surface. 
Univariate regression analyses confirmed significant, 
negative, linear associations between the eGFR on one 
hand and the osteoid volume (r2 = 0.17, p = 0.004), 
osteoblast surface (r2 = 0.26, p < 0.001), fibrosis 
volume (r2 = 0.10, p = 0.03) and bone formation rate 
(r2 = 0.21, p < 0.001) on the other, as well as a positive 
association between the eGFR and the mineralization 
lag time (r2 = 0.09, p = 0.03).
The associations between total IS serum levels 
and biochemical parameters related to mineral 
metabolism are shown in Table 3. A positive, linear 
association with phosphate, FGF-23 levels and iPTH 
levels and a negative association with 1,25 D levels 
were also noted.
Regarding the bone histomorphometric parameters, 
IS associated positively with the bone formation rate, 
osteoid volume, osteoblast surface and fibrosis volume 
(Table 4). Similar associations were observed with iPTH 
levels and the same histomorphometric parameters. 
Multivariate regression models (Table 5), revealed 
that the positive associations between IS serum levels 
on one hand, and the osteoblast surface and the bone 
fibrosis volume on the other were independent of the 
cohort’s demographic characteristics and biochemical 
parameters related to mineral metabolism, such as 
iPTH, FGF-23, 25D and bicarbonate. A similar trend 
was observed for the bone formation rate.
dIscussIon
The present study suggests that under “real-life” 
conditions, IS levels are positively associated with the bone 
formation rate. This observation appears to contradict 
in vitro and animal studies, which reported an inhibitory 
effect of IS on bone formation, osteoblast-related gene 
tAble 1 biochemicAl And hormonAl chArActeriSticS of the Study populAtion, by cKd StAge
CKD stage
2 and 3 
n = 29
4 and 5 
n = 20
p
Bicarbonate (mM) 24.6 ± 2.9 22.6 ± 2.9 0.03
Ionized calcium (mM) 1.31 ± 0.04 1.28 ± 0.07 0.1
Phosphate (mg/dL) 3.5 ± 0.6 4.3 ± 0.6 < 0.001
Intact-PTH (pg/ml) 75 (41-99) 195 (99-366) < 0.001
Total alkaline phosphatase (U/L) 113 (69-163) 118 (76-167) 0.6
bAP (U/L) 23 (17-28) 31 (21-46) 0.007
FGF-23 (pg/ml) 45.8 ± 30.1 95.8 ± 69.5 0.001
25 (OH) vitamin D (pg/ml) 33 ± 9 28 ± 10 0.05
1,25 (OH)2 vitamin D (ng/dL) 38 (33-49) 33 (25-39) 0.02
Total indoxyl sulfate (mg/dL) 0.16 (0.09-0.22) 0.44 (0.35-0.68) < 0.001
Free indoxyl sulfate (mg/dL) 0.028 (0.025-0.032) 0.041 (0.035-0.050) 0.003
Data are quoted as mean ± SD or, for variables with a non-Gaussian distribution, median (percentile 25th-75th). bAP: bone-specific alkaline 
phosphatase; FGF: Fibroblast growth factor; PTH: Parathyroid hormone.
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Figure 1. Exponential association between serum total IS levels and 
the estimated glomerular filtration rate; r2 = 0.47, p < 0.001, n = 49. 
The dotted line indicates the reference value in 20 healthy control 
subjects.
tAble 2 bone hiStomorphometric pArAmeterS of the Study populAtion, by cKd StAge
CKD stage
2 and 3 
n = 29





BV/TV (%) 17.02 ± 5.46 17.50 ± 5.67 0.9 20.95 ± 5.94
OV/BV (%) 0.95 (0.27-2.32) 2.31 (1.41-4.60) 0.003 2.18 ± 2.98
Ob.S/BS (%) 0.66 (0.16-1.34) 2.22 (1.05-4.35) 0.001 1.26 ± 2.44
ES/BS (%) 7.29 ± 6.72 8.72 ± 6.09 0.4 1.51 ± 1.27
Oc.S/BS (%) 0.22 (0.05-0.87) 0.70 (0.31-1.62) 0.015 0.01 ± 0.03
Fb.V (%) 0.6 (0-2) 1.5 (0.7-9.7) 0.02 < 0.5
BFR/BS (μm3/μm2/d) 0.001 (0.001-0.020) 0.010 (0.008-0.037) 0.004 0.04 ± 0.002
Mlt (d) 151 (34-655) 78 (31-181) 0.06 19 ± 7
Data are quoted as the mean ± SD or (for variables with a non-Gaussian distribution) the median (percentile 25-75). BV/TV: Trabecular bone volume/
tissue volume; OV/BV: Osteoid volume/trabecular bone volume; Ob.S/BS: Osteoblast surface /bone surface; ES/BS: Eroded surface/bone surface; 
Oc.S/BS: Osteoclast surface/bone surface; Fb.V: Bone fibrosis volume; BFR/BS: Bone formation rate/bone surface; Mlt: Mineralization lag time.
tAble 3 univAriAte lineAr ASSociAtionS between Serum totAl iS levelS And minerAl metAboliSm pArAmeterS
R2 β (95% CI) p
Bicarbonate 0.13 -0.03 (-0.05- -0.007) 0.01
Ionized calcium 0.07 -1.1 (-2.2- -0.1) 0.1
Phosphate 0.22 0.16 (0.07-0.25) 0.001
intact-PTH 0.27 0.15 (0.08-0.23) < 0.001
Total alkaline phosphatase 0.002 0.40 (-0.15-0.10) 0.7
Bone-specific alkaline phosphatase 0.25 0.15 (-0.02-0.32) 0.1
FGF-23 0.25 0.002 (0.001-0.003) < 0.001
25 (OH) vitamin D 0.03 -0.004 (-0.01-0.003) 0.2
1,25 (OH)2 vitamin D 0.16 -0.26 (-0.43- -0.10) 0.004
CI: Confidence interval; FGF: Fibroblast growth factor; PTH: Parathyroid hormone.
expression and both osteoblast and osteoclast cell 
viability.9-11,21 However, the animal studies in question 
were performed in thyroparathyroidectomized uremic 
rats in which physiological plasma PTH concentrations 
were restored by infusion.9,21 The inability to develop 
secondary hyperparathyroidism thus constitutes a 
limitation of this model. Although valid as a controlled, 
experimental data, the reported observations might be 
irreproducible under true clinical conditions, where 
impaired renal function is most frequently associated 
with supra normal increases in PTH secretion.22
Other important point of the present study is that we 
confirm previous studies that have suggested that low 
bone turnover might characterize ROD in early-stage 
CKD.23 As suggested by observations in a murine model 
of CKD without secondary hyperparathyroidism23 and 
a number of clinical studies,4,24,25 the slight increase in 
PTH levels in early-stage CKD might not be sufficient 
to counterbalance certain bone anabolism-suppressive 
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tAble 4 univAriAte lineAr ASSociAtionS between bone hiStomorphometric pArAmeterS on one hAnd And Serum  
 totAl iS And intAct-pth levelS on the other
Indoxyl sulfate Intact-PTH
R2 β (95% CI) p R2 β (95% CI) p
BV/TV 0.002 -0.002 (-0.01-0.01) 0.8 0.001 0.004 (-0.04-0.05) 0.8
OV/BV 0.15 0.07 (0.02-0.12) 0.006 0.33 0.34 (0.20-0.49) < 0.001
Ob.S/BS 0.26 0.11 (0.05-0.17) < 0.001 0.18 0.30 (0.10-0.50) 0.004
ES/BS 0.03 0.006 (-0.004-0.02) 0.2 0.03 0.02 (-0.16-0.06) 0.3
Oc.S/BS 0.04 0.04 (-0.02-0.10) 0.2 0.12 0.23 (0.04-0.42) 0.02
Fb.V 0.31 1.31 (0.73-1.90) < 0.001 0.19 3.5 (1.3-5.6) 0.002
BFR/BS 0.16 0.06 (0.02-0.10) 0.004 0.14 0.19 (0.06-0.33) 0.007
Mlt 0.04 -0.04 (-0.09-0.02) 0.2 < 0.001 -0.006 (-0.19-0.18) 0.9
CI: Confidence interval; the other abbreviations are as in Table 2.
tAble 5 multivAriAte lineAr regreSSion modelS. ASSociAtionS between Serum iS levelS And bone    
 hiStomorphometric pArAmeterS
β (95% CI) p
OV/BV 








Model’s r2 = 0.34b
Indoxyl sulfate 1.6 (0.1-3.1) 0.04
Fb.V 















a Variables included in the model: indoxyl sulfate, ionized calcium, FGF-23, intact-PTH; b Variables included in the model: indoxyl sulfate, bicarbonate; 
FGF-23, 1,25-OH-vitamin D3, intact-PTH; 
c Variables included in the model: indoxyl sulfate, age, ionized calcium, intact-PTH; d Variables included in 
the model: indoxyl sulfate, age, intact-PTH; Abbreviations are as in Table 2.
factors already present (such as gonadal hormone 
deficiency, diabetes and decreased calcitriol).23,26 It is 
important to note that none of the patients enrolled in 
the present study had ever been treated with vitamin 
D analogues, calcium or aluminum-based phosphate 
binders or drugs associated with low bone turnover. 
Hence, in contrast to earlier reports in hemodialysis 
patients, possible iatrogenic effects of these drugs 
cannot be implicated in the lower bone turnover 
observed in this study.
One explanation for the apparently conflict 
between our present clinical observation and the 
preclinical work in the literature relates to the fact 
that higher IS levels may affect PTH secretion by 
either participating in skeletal resistance to PTH 
or by decreasing calcitriol synthesis/action. The 
hyperparathyroidism, commonly present in the 
uremic state would then clinically override the local 
inhibitory action of IS on bone turnover. There are at 
least two major arguments in favor of this hypothesis.
Firstly, it has been demonstrated that uremia is 
associated with down-regulation/desensitization of 
the PTH1R, that contributes to the skeletal resistance 
to PTH observed in the uremic setting.27 Importantly, 
this condition is neither prevented nor corrected 
by parathyroidectomy.28 It has subsequently been 
reported that factors other than PTH present in the 
uremic ultrafiltrate decrease PTH-stimulated cAMP 
generation in cultured osteoblast-like cells via a 
decrease in the levels of PTH1R mRNA.29 More 
specifically, Nii-Kono et al. demonstrated that IS 
reduced PTH-induced cAMP production, PTH1R 
gene expression and cell viability in primary osteoblast 
cell cultures.10 Thus, uremic toxins, and particularly 
IS, may be directly involved in the development of 
bone resistance to PTH. The latter condition may 
stimulate PTH synthesis aggravating the secondary 
hyperparathyroidism and leading to higher bone 
turnover in later CKD stages. In accordance with 
this hypothesis, our early-stage CKD patients, that 
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presented only slightly elevated iPTH levels but 
significantly elevated serum IS levels, had extremely 
low bone formation rate. This possibly reflects an 
initial, preponderant inhibitory action of IS on bone 
turnover prior to major elevation of PTH levels.
Secondly, calcitriol availability may be affected 
by IS. In addition to classical factors known to 
reduce calcitriol synthesis (i.e. decreased renal mass, 
hyperphosphatemia, increased FGF-23 levels and 
metabolic acidosis), phosphate-free uremic plasma 
has also been shown to directly inhibit 1α-hydroxylase 
activity and thus decrease calcitriol availability.30 
Calcitriol exerts its biologic action by binding to the 
nuclear vitamin D receptor (VDR). Under normal 
conditions, calcitriol suppresses PTH secretion by 
directly binding to VDRs in the parathyroid gland. 
Patel et al.31 have elegantly demonstrated that 
VDRs isolated from rats with kidney failure and, 
subsequently, incubated with uremic ultrafiltrate 
presented a reduction in specific DNA binding 
capacity, which could not be explained by impaired 
VDR expression. The authors concluded that toxins 
present in the uremic ultrafiltrate interacted with 
the VDR to impair its DNA binding capacity within 
cells and could thus diminish the calcitriol response 
in kidney failure. Although further studies have 
identified a role for purines in this process,32,33 it 
is likely that other compounds are involved. By 
studying subfractions of uremic plasma, Hsu et al.32 
further demonstrated that other substances, which 
included IS among them, could also interfere on 
calcitriol metabolism. Moreover, a preliminary study 
has shown that rats with kidney failure fed with 
a high-protein diet presented significantly lower 
calcitriol levels than animals fed a normal diet, in the 
absence of intergroup differences in phosphate intake 
and creatinine clearance.32,34 Since higher protein 
intake results in greater IS levels,35 this observation 
further suggests that IS has a negative effect on 
calcitriol synthesis. Our finding in the present cohort 
of a negative association between 1,25 D and IS 
serum levels corroborates to this hypothesis.
Our study’s strong points include the first ever 
evaluation in a clinical setting of biochemical and 
hormonal factors related to mineral metabolism 
and bone histomorphometry and their association 
with IS, a protein-bound uremic toxin prototype, in 
asymptomatic, treatment-naïve patients at different 
pre-dialysis CKD stages. Limitations of our study 
include the small cohort size. Additionally, due to the 
inverse relationship between GFR and IS levels (as 
depicted in Figure 1), it is not possible to differentiate 
whether the observed association between this uremic 
toxin and bone histomorphometric parameters is 
independent of kidney function loss. Actually, the 
study’s epidemiological, cross-sectional design does 
not enable cause-effect relationships to be evaluated. 
Hence, the present study should be considered as 
generating hypotheses, which should be tested in 
infusion studies in animals and then confirmed by 
interventional clinical trials.
conclusIons
The results of the present study demonstrated that 
the uremic toxin IS is positively associated with bone 
formation rate, osteoid volume, osteoblast surface 
and fibrosis volume in a CKD setting - possibly by 
increasing PTH secretion (via an increase in skeletal 
resistance to PTH or via calcitriol inhibition) - 
suggesting that IS may play a role in the pathogenesis 
or ROD in the pre-dialysis setting.
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